Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
European Commission gives an expected conditional regulatory approval for the acquisition of Shire by Takeda, removing the last potential antitrust hurdle to the deal, meaning that attention is now turning to the upcoming shareholders' meetings that would open the final path to the early January completion of the record-setting transaction.
Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
Takeda is hoping to start 2019 with a bang, saying its huge acquisition of Shire might become a done deal as early as January 8. Speculation continues meanwhile on possible post-merger divestments to help pay down associated debt.
The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia and renaming itself as it remains hopeful of progressing its core investigational asset in a targeted population of Alzheimer’s disease patients.
European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.
While multiple new approaches and drugs are being developed for different stages of prostate cancer globally, many remain unavailable across Asia Pacific markets, despite a rising overall incidence of the disease. Two specialists recently shared with Scrip their views on treatment issues and optimum approaches in this fast-changing environment, and how they see the broader role of existing and new therapies developing given recent clinical results and practice.